New York, New York, April 5, 2024 – Acarix, a leader in advanced acoustic-based cardiac diagnostics announces the submission of an application for cross-trading of the Acarix share on the OTCQB trading platform. Upon approval, Acarix shares will in parallel to its current First North Growth Market listing, be traded with a US ticker symbol and a share price in USD.
OTCQB is a trading platform in the United States operated by the OTC Markets Group, as an alternative to listing on Nasdaq New York and NYSE. Cross-trading on OTCQB helps satisfy an increasing interest from US investors and increase accessibility to the US capital market. Upon approval, Acarix shares will be traded with a US ticker symbol and a share price in USD, during US market hours.
"After registration of the latest directed share issue, around 20 percent of the shares in Acarix are held by US investors, and our commercial focus is on the US market. As a result, we want to make it easier for US investors to trade in the Acarix share”, comments Aamir Mahmood, CEO of Acarix AB.
